These immune-antagonizing activities of HCV explain why most HCV patients fail to eradicate this virus and eventually develop severe liver diseases and why IFN therapies did not generate sustained response in the majority of patients infected by HCV. This evidence concerns the gene IFNA1 and liver disorder.